A reduction was seen in the risk for readmission, wound dehiscence and hematoma, but no significant differences were seen in rates of infection and bleeding.
The US Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial ...
The senior living market has entered 2025 with both challenges and opportunities, testing the industry’s resilience and innovation as it navigates a dynamic economic and political landscape, according ...
In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...